Arterial stiffness has recently been recognised as an independent risk factor for cardiovascular morbidity and mortality in hypertension. Many of the complications seen with angiotensin II (Ang II) excess or hyperaldosteronism -an increased event rate, left ventricular hypertrophy, endothelial dysfunction and target organ damage -are also associated with arterial stiffness. It is possible that reduced arterial compliance may be one mechanism whereby increased activity of the renin-angiotensin-aldosterone system (RAAS) produces adverse vascular effects. Common pathophysiological processes, altered collagen turnover and increased fibrosis may underlie both arterial stiffness and RAAS-associated vascular damage.
Introduction
The pulse has retained a central role throughout the history of medicine. It was, however, more an art than a science until the 19th century, when sphygmography provided the first graphic recordings of the arterial pressure pulse. Abnormalities in the pulse wave contour were considered indicative of stiff arteries and subsequently used to diagnose hypertension and Bright's disease.About the same time as Tigerstedt and Bergman discovered renin, sphygmography was abandoned in favour of cuff sphygmomanometry. There has been a recent awakening in the field of arterial stiffness follow-ing the development of highly reproducible invasive and non-invasive techniques. These have opened new vistas in our understanding of blood pressure (BP) regulation and essential hypertension. We have come to appreciate that pathophysiological mechanisms of hypertension include not only vascular resistance, the classical hallmark of high BP, but also changes of arterial compliance and wave reflections, which involve conduit arteries.
The ancient Chinese were the first to describe what we now believe is a link between the reninangiotensin-aldosterone system (RAAS) and arterial stiffness, when they observed the hardening of the arteries due to excess salt. While the RAAS was mainly considered to act on the arterioles, the relationship between large artery structure and function and this important system remained obscure. In the past few years, quantitative techniques have established, both in clinical and experimental hypertension, significant links between the large arteries and the RAAS.
The aim of this review is to present evidence that not only is the structure and function of the large arteries modulated by the RAAS, but that they also respond actively to RAAS blockade, in part independently of BP. This may produce an additional pathway to reduce cardiovascular events.
Concepts of arterial stiffness and wave reflection
The arterial system consists of elastic conduits, particularly the aorta and its major branches, peripheral muscular arteries, namely the brachial, radial and femoral arteries, and high resistance arterioles. One function of this elaborate system is to convert the pulsatile flow of the heart to a steady flow through the capillaries.The heart is an intermittent pump, which discharges the entire stroke volume during systole. Part of the energy of cardiac contraction is dissipated as capillary flow during systole; the remainder is stored in the large arteries as potential energy by stretching the elastic arterial walls. During diastole, the elastic recoil of the arterial walls converts the potential energy into capillary flow. If the arterial walls were rigid, capillary flow would cease during diastole, with detrimental consequences, especially for the subendocardium of the heart itself, as it does not receive any perfusion during cardiac systole.This ability of the aorta to respond to pressure changes with appropriate alteration in diameter
is the measure of its compliance, and the relative changes in its diameter in relation to a pressure change is called distensibility ( Table 1) . The radial stretch of the aorta brought about by left ventricular ejection generates a pressure wave that is propagated down the aorta and its branches, at a measurable velocity (see Table 1 ). The pulse wave velocity (PWV) increases as arteries stiffen with age and hypertension and for the aorta ranges between 5-20 m/sec. 1 Aortic PWV has proved to be an independent marker of cardiovascular risk and of greater importance than any single measurement of BP. [2] [3] [4] A recent eightyear follow-up study of 715 hypertensive patients confirms that PWV is a more sensitive prognostic index than either pulse pressure (PP) or systolic pressure (SP). 5 In a 10-year follow-up study of patients with end-stage renal disease on antihypertensive therapy, particularly angiotensin-converting enzyme (ACE) inhibitors, there was a marked significant survival advantage for patients who showed a reduction in aortic PWV compared with those whose PWV continued to increase. 6 Arterial PWV also increases as the pulse travels from the aorta towards the periphery; consequently, arterial stiffness is greater in the peripheral vessels, resulting in a higher PP in the peripheral than in the central arteries, a phenomenon called PP amplification. This ranges between 12-20 mmHg in health,is reduced in stiff arteries and is an important prognosticator for cardiovascular events in patients with end-stage renal disease. 7 The pressure pulse travels faster than blood itself and when it encounters the high-resistance arterioles in the periphery, it is reflected back towards the heart. In healthy elastic arteries, the reflected wave arrives back at the aorta during diastole ( Figure 1A) , increasing coronary perfusion pressure. However, as arteries stiffen and the PWV increases, the reflected wave arrives too early at the heart, before the aortic valve has closed i.e. during systole ( Figure 1B ).This increas-es left ventricular afterload and minimises coronary perfusion pressure, and can result in left ventricular hypertrophy and left ventricular failure on one hand, and subendocardial ischaemia and coronary heart disease on the other. 8 These early and accentuated reflections in the aorta augment the late SP and thus the absolute systolic BP and are the major determinant of PP. The extent of this wave reflection is expressed as the augmentation index (AIx) (see Table 1 & Figure 1C ).There is evidence that the AIx is a significant predictor of coronary artery disease 9 and independent prognosticator of cardiovascular morbidity and mortality in patients with end-stage renal disease. 10 This form of arterial wave analysis can be used to monitor the effects of drug therapy, as illustrated in Figure 2 . Commonly both PWV, representing large artery stiffness, and AIx, representing both large and smaller artery stiffness, are measured for a more complete evaluation of vascular stiffness.
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Table 1 Definitions of different arterial stiffness parameters
Arterial compliance
Absolute diameter change (∆D) for a given pressure (∆P) change at fixed vessel length ∆D/∆P(cm 3 .mmHg -1 )
Arterial distensibility
Relative diameter change (∆D/D) for a given pressure increment(∆P) ∆D(∆P.D) (mmHg -1 )
Pulse wave velocity Speed of travel of the pulse along an arterial segment Distance/∆transit time(m/sec)
Augmentation index
The difference in height between the first and second systolic peaks (augmentation pressure [AP]) in the aortic waveform expressed as a percentage of aortic pulse pressure AP/aortic pulse pressure (%) Figure 1 The radial and aortic pressure waveforms in a healthy (A) and a hypertensive (B) age-matched subject. Note a single systolic peak in the aortic pressure waveform and the diastolic timing of the reflected wave, more obvious in the radial waveform in the healthy subject. In contrast, a second systolic peak, higher than the first, can be seen in the aortic pressure waveform with the reflected wave appearing in systole in the hypertensive subject.The augmentation index is calculated (augmentation pressure/pulse pressure) from the derived aortic pressure waveform (C) 
Effects of RAAS on arterial stiffness
Data relating the activity of the RAAS to arterial stiffness, both in normotension and essential hypertension, are far from complete.The RAAS is traditionally described as acting predominantly on the arterioles with resulting vasoconstriction. However,such modulating mechanisms involve not only arteriolar, but also large artery modification of structure and function, the former by altering collagen and elastin and the latter by vasoactive neurohormones. As sodium and water depletion induce powerful modulating mechanisms involving mainly the RAAS, studies looking at the effect of salt in both animal models and man can be quite informative. In stroke-prone spontaneously hypertensive rats (SHR), increased sodium intake was associated with more pronounced structural alterations of cerebral and renal arteries, compared with a low-sodium diet. 11 In essential hypertension, inadequate suppression of aldosterone in response to increased sodium intake is related to both impaired ventricular systolic and diastolic function. 12 A longitudinal study in normotensive subjects has shown significant associations between increased sodium intake and enhanced isobaric aortic stiffness. 13 These findings are consistent with the observation that in older patients with systolic hypertension, dietary restriction of salt led to a significant reduction in urinary sodium excretion and carotid artery compliance, accompanied by a reduction in systolic BP. 14 In contrast, in a study of hypertensive subjects, moderate salt restriction lowers BP while causing a parallel dilatation of the muscular brachial artery, but not of the elastic carotid. 15 One of the mechanisms by which the RAAS may alter arterial stiffness is through the potent vasoconstrictor, angiotensin II (Ang II). In healthy volunteers,Ang II infusion increases PWV in a way which is only partly BP-dependent. 16 It also increases AIx and aortic PP without any concomitant change in peripheral PP. 17 There is also some evidence that the detrimental effect of Ang II on arterial stiffness is mediated by the AT 1 -receptor. 18 Ang II has also been shown to impair cardiac diastolic function in healthy humans. 19 There are significant associations between arterial stiffness and the AT 1 -receptor gene polymorphism 20 G-protein β 3 subunit -C825T in healthy young men, 21 the angiotensinogen TT genotype at position 235 22 and insertion/deletion (1/D) polymorphism 1D/DD of the ACE gene. 23 Studies have also found links between aortic stiffness and gene polymorphisms specifically linked to elastin, 24 collagen, 25 or the reduction of telomere length with age. 26 The underlying structural changes seen with enhanced Ang II activity, collagen degradation, smooth muscle proliferation and the development of fibrosis are very much in keeping with the underlying pathophysiological mechanisms that increase arterial stiffness. 27 Matrix metalloproteinases (MMPs), which modulate collagen and elastin turnover in the vascular wall, may also play a significant role, for example, MMP 9 genotype influences large artery stiffness through effects on aortic gene and protein expression. 28 Because of the heterogeneity of the arterial system, it is unlikely that the influence of gene polymorphisms will be limited to a single gene. Furthermore, environmental factors affecting the RAAS play a major role in the increase in aortic stiffness, such as sodium intake and the changes in sodium sensitivity with ageing. Historically, Ang II has been viewed as a primary factor causing adverse functional and structural alterations in the vessel wall. However, substantial evidence has emerged to show that aldosterone also plays an independent role in mediating cardiovascular damage. It plays a major role in cardiac and vascular remodelling, regulating collagen turnover and fibrous tissue formation, though some evidence suggests that it may have short-term vascular effects, leading to vasoconstriction in both in vitro studies 29 and in vivo in man. 30, 31 Long-term increases in aldosterone lead to deleterious effects on the vascular matrix, by increasing collagen content and fibrosis. 32 Patients with hyperaldosteronism have greater cardiovascular risk, left ventricular hypertrophy and end-organ damage. 33 There is increasing evidence to suggest a BP-independent effect of aldosterone on the cardiovascular system, with increased collagen deposition and fibrosis seen both in the ventricle and the arterial wall and immunohistochemical evidence suggests the presence of aldosterone receptors in the aorta. 33 Experimentally, aldosterone increases arterial stiffness and PP in salt-fed rats through changes in the elastin and collagen densities, an effect that is prevented by the specific aldosterone antagonist, eplerenone. 34 In the Randomised ALdactone Evaluation Study (RALES) of spironolactone in congestive heart failure,
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Figure 2
Serial radial (left panel) and aortic (right panel) pressure waveforms in a hypertensive subject at two-weekly intervals, at baseline (A) and following angiotensin receptor blocker (ARB) (B), angiotensinconverting enzyme inhibitor (ACE-I) (D). Note the reduction in late systolic augmentation pressure in the aortic pressure waveform after treatment with either valsartan 160 mg/d (B) or captopril 100 mg/d (D) and the increase after the wash out period (C). In the radial pressure wave, the reflected wave shifts favourably from systole to diastole during therapy. Both these changes are greater with combined ACE-I and ARB therapy (E) limitation of the excessive extra cellular matrix turnover (particularly pro-collagen III) by spironolactone appeared to contribute to survival advantage. 35 Blacher et al. 36 have shown a relationship between increased plasma levels of aldosterone and decreased systemic compliance in patients with long-standing hypertension. Resnick et al. demonstrated a significant inverse relationship between plasma renin activity and the baseline level of both large and small artery compliance in normotensive subjects. 37 We have recently found a significant positive correlation between the aldosterone renin ratio (ARR) and aortic systolic BP, aortic PP and AIx, but not PWV, and negative correlations with PP amplification in untreated hypertensive patients. 38 Pojoga et al. 39 did not find any relationship between plasma renin or aldosterone levels and PWV in 216 patients with mild-to-moderate hypertension. They did, however, show a significant relationship between plasma aldosterone levels and aldosterone synthase polymorphism in a subgroup of patients who also had a higher PWV. Further strengthening the relationship between aldosterone and arterial stiffness, hyperaldosteronism is associated with impaired baroreflex functions and reduced aortic compliance. 40 In hypertensive patients, exercise systolic BP and the change in systolic BP during exercise were independently related to ARR -a relationship related to reduced vascular compliance which impairs the systolic response to exercise. 41
Effect of drug therapy
The effect of commonly used antihypertensive agents on arterial stiffness, as assessed by PWV and AIx, is shown in Table 2 (adapted from reference 42 ). Data in relation to the RAAS is most consistent with ACE inhibitors (ACE-Is), ARBs and spironolactone antagonists, all reducing stiffness (Table 3) .
ACE inhibitors
In an invasive study 43 following intra-arterial captopril in hypertensive patients, large artery compliance was significantly increased. Subsequently, Topouchian 44 showed that the acute administration of quinapril increased carotid artery distensibility and decreased PWV and wave reflections, an effect that was in part independent of BP reduction. A number of other studies have confirmed that other ACE-Is similarly reduce arterial stiffness (see Table 3 ).
A number of important points have emerged. Reduction in arterial stiffness (PWV) in hypertensive subjects following ramipril was unrelated to the extent of BP reduction. 45 BP has an important influence on PWV and wave reflection. BP-independent reduction in arterial stiffness may indicate effects on the arterial wall structure due to ACE inhibition. As mentioned earlier, a survival advantage was seen in patients with end-stage renal disease in whom PWV was reduced as opposed to BP reduction. 6 The effect of lisinopril on stiffness may extend beyond its antihypertensive effect, suggesting structural changes; the effect persisted for at least four weeks following withdrawal of lisinopril. 46 Trandolopril 47 increased brachial artery compliance and reversed left ventricular hypertrophy and decreased arterial wall stiffness in hypertensive subjects treated for one year. Again, the benefit persisted for one month after discontinuation of treatment. Quinapril decreased PWV, left ventricular hypertrophy and iliac intimal medial thickness independently of the BP reduction in a six-month study of hypertensive subjects. 48 Antihypertensive doses of perindopril, but not hydralazine, were shown to prevent chronic accumulation of aortic collagen. The collagen reduction was noticed with non-hypertensive doses of perindopril and paralleled the decrease in ACE-activity measured in the aorta tissue but not in the plasma of rats. 49 ACE inhibition improves large artery compliance independently of BP changes, 50 probably by acute functional changes involving vascular smooth muscle relaxation and improved endothelial function and in the long term by decreased arterial wall thickness, collagen content, and reversion of smooth muscle cell hypertrophy. 51 This is discussed further in the next section.
Aldosterone antagonist
The effects of ACE inhibition on arterial stiffness are more pronounced in the presence of certain gene polymorphisms, such as the AT 1receptor gene polymorphism. 52
Angiotensin II receptor blockers
Given the favourable effects of ACE inhibition, it was not unexpected that ARBs had similar effects. The ARB, valsartan, was added to therapy for two weeks in poorly controlled hypertensives who were on at least three antihypertensive drugs, including an ACE-I. Arterial wave reflections measured by the AIx were significantly reduced. 53 In a four-week crossover study with losartan, compared with hydrochlorthiazide, in patients with essential hypertension,for the same BP reduction,only losartan decreased PWV and aortic AIx and enhanced PP amplification. 54 Similar results have been seen with valsartan. 55 The decrease in PWV and arterial wave reflection appeared to be independent of BP reduction. Using finger plethysmography, losartan increased arterial compliance after four weeks' treatment. 56 There was no correlation between the reduction in BP and the effect on arterial compliance, suggesting a BP-independent effect. Schriffrin and colleagues treated hypertensive patients with either losartan or atenolol for one year. 57 BP was reduced comparably in both groups, but only in the losartan-treated patients was there a decrease in the media:lumen ratio of microvasculature obtained from subcutaneous gluteal biopsy specimens and an improvement in acetylcholine-induced endothelial-dependent relaxation. In a clinical study of hypertensive Type 2 diabetic patients, telmisartan significantly reduced PWV and wave reflection compared with placebo. 58 In normotensive subjects, subjects with the highest renin had the greatest improvement in arterial compliance with olmesartan. 37 In a randomised, crossover study in hypertensive patients comparing valsartan, 160 mg/day, with captopril, 100 mg/day, both therapies produced a similar reduction in PWV and AIx, which remained significant when corrected for BP reduction. Of note, when both therapies were combined, the reduction in arterial stiffness was significantly greater than with either monotherapy, even when corrected for the greater BP reduction with the combined regimen (Figure 3 ). 59 The study raises the possibility that agents that independently reduce arterial stiffness may have an additive effect in combination. 59 The mechanisms underlying the effects of ARBs are likely to be similar to those of ACE inhibition, but may involve additional pathways. The ARB, candesartan, improved tonic nitric oxide (NO) release and reduced vasoconstriction to endogenous endothelin 1 in the forearm of hypertensive patients after 12 months' therapy. 60 Improved endothelial dysfunction with increased bioavailability of NO is also seen following four weeks' therapy with losartan. 61 Both ARBs and ACE-Is affect the same pressor system; however, because they act on different sites, they may have additive or synergistic effects producing a more complete blockade including local and non-ACE pathways. Also,the ancillary properties of both ACE-I (e.g. interruption of bradykinin metabolism and interaction with NO) and of ARBs (e.g. interaction with prostaglandins and NO) may be synergistic when the two groups are combined. 62 In addition, the recommended doses of ACE-Is may provide only partial inhibition of ACE. 63
Aldosterone antagonism
In recent years, several in vitro investigations have indicated that aldosterone may act directly on large arterial vessels. Immunohistochemical studies have shown that the mineralocorticoid receptors predominate in the aorta and their distribution decreases with the size of the arteries. 64 In hypertensive subjects, increased aortic stiffness and plasma aldosterone levels are statistically associated in some 36 but not all studies. 39 In hypertensive patients, a study of two weeks duration did not identify a change in brachial artery stiffness after administration of spironolactone, 65 but this muscular artery may not be an appropriate site to study stiffness. Six weeks' treatment in an open study with the aldosterone antagonist, canreonate, 50 mg daily, did not alter PWV in a hypertensive population. 66 More recently, however, in a randomised controlled one-month study in a hypertensive population, comparing spironolactone 50 mg to bendrofluazide 2.5 mg, only spironolactone reduced PWV and AIx and, following adjustment for change in BP, the reductions remain significant; 67 hypertensive patients with the highest ARR had the greatest fall in aortic BP and AIx%. 38 The more selective aldosterone antagonist, eplerenone, has also been shown in a comparative study to reduce aortic PWV in patients with systolic hypertension and wide PP. 68
Conclusion
The experimental animal data, showing similarities in pathophysiological structural changes seen with aldosterone and angiotensin excess, together with the consistent data in man showing that blockade of the RAAS reduces arterial stiffness, is suggestive of a causal link. As arterial stiffness is emerging as a therapeutic target in its own right, we need to explore the potential beneficial effects of RAAS blockade on arterial stiffness, beyond BP reduction. 
